Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.110
+0.060 (2.92%)
Nov 21, 2024, 12:59 PM EST - Market open
Allogene Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for ALLO stock have an average target of 10.06, with a low estimate of 4.60 and a high estimate of 14. The average target predicts an increase of 376.78% from the current stock price of 2.11.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ALLO stock from 12 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 4 | 4 | 4 | 4 |
| Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 12 | 12 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $11 → $9 | Buy | Maintains | $11 → $9 | +326.54% | Nov 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +326.54% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +326.54% | Oct 30, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +326.54% | Aug 15, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $7 → $8 | Strong Buy | Maintains | $7 → $8 | +279.15% | Aug 9, 2024 |
Financial Forecast
Revenue This Year
65.67K
from 95.00K
Decreased by -30.88%
Revenue Next Year
3.94M
from 65.67K
Increased by 5,902.96%
EPS This Year
-1.51
from -2.09
EPS Next Year
-1.42
from -1.51
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 231,000 | 64.0M | 194.3M | ||
| Avg | 65,668 | 3.9M | 18.3M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 143.2% | 97,384.9% | 4,828.0% | ||
| Avg | -30.9% | 5,903.0% | 364.9% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.37 | -1.05 | -1.07 | ||
| Avg | -1.51 | -1.42 | -1.54 | ||
| Low | -2.94 | -1.68 | -2.14 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.